Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. | Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. | Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. | Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections. | |
Founding Date | Founding Date 2008 | Founding Date 2003 | Founding Date 2013 | Founding Date 1979 |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Private |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Tomsk, RU Ufa, RU | Locations San Diego, US HQ | Locations Lausanne, CH HQ Oss, NL |
Employees | Employees 53611% increase | Employees 1,15526% decrease | Employees 57 | Employees 501 |
Financial | ||||
Revenue (est.) | Revenue (est.) $26.8m (FY, 2023) | Revenue (est.) ₽142.9b (FY, 2023) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) N/A |
Cost of goods | Cost of goods $2.9m (FY, 2023) | Cost of goods ₽109.3b (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $23.9m (FY, 2023) | Gross profit ₽33.6b (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($352.1m) (FY, 2023) | Net income ₽23.3b (FY, 2023) | Net income ($236.6m) (FY, 2021) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 144.4m | Total funding raised $ 2.1m |